Targeting cancer treatment to reduce side effects
Antigen-targeted activation of Topo1 inhibitors via click chemistry
['FUNDING_SBIR_2'] · SHASQI, INC. · NIH-11007506
This study is looking at a new way to make cancer treatment better by using a special method to deliver medicine directly to tumors, which could help reduce side effects and make the treatment more effective for patients.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SHASQI, INC. (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-11007506 on ClinicalTrials.gov |
What this research studies
This research focuses on improving cancer treatment by using a method called click chemistry to specifically activate Topo1 inhibitors at the site of tumors. By targeting the drugs directly to the cancer cells, the goal is to minimize the toxic side effects that often occur with traditional chemotherapy. Patients may benefit from a more effective treatment that reduces the need for high doses and lowers the risk of adverse drug effects. The approach aims to enhance the delivery and efficacy of existing cancer therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research would be patients diagnosed with cancers that are currently treated with Topo1 inhibitors and who experience significant side effects from conventional therapies.
Not a fit: Patients with cancers that do not respond to Topo1 inhibitors or those who are not eligible for chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments with fewer side effects for patients.
How similar studies have performed: Previous research has shown promise in using targeted therapies to improve cancer treatment outcomes, suggesting that this approach may be effective.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- SHASQI, INC. — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MEJIA ONETO, JOSE M — SHASQI, INC.
- Study coordinator: MEJIA ONETO, JOSE M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.